NCT02245841View on ClinicalTrials.gov

Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis

PHASE4CompletedINTERVENTIONAL

Enrollment

19

Participants

Timeline

Start Date

June 15, 2015

Primary Completion Date

July 14, 2021

Study Completion Date

July 14, 2021

Conditions

DermatomyositisJuvenile Dermatomyositis

Interventions

DRUG

H.P. Acthar Gel

80 U (1 mL) of H.P. Acthar gel via subcutaneous injection twice weekly for 24 weeks

Trial Locations (1)

44195

Cleveland Clinic, Cleveland

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Mallinckrodt

INDUSTRY

lead

The Cleveland Clinic

OTHER

NCT02245841 - Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis | Biotech Hunter | Biotech Hunter